According to WHO, 254 million people globally were estimated to have HBV in 2022, but only approximately 10% had been ...

Shares of Precision BioSciences DTIL rallied 23.8% on Tuesday after the company’s announcement that the FDA has granted Fast ...

China: A recent retrospective cohort study has highlighted the significant role of pulmonary infections in influencing ...

Catching HBV early can make a world of difference. Medical professionals typically use blood tests that check for signs of the virus in the body, such as HBV antigens or antibodies. They also ...

The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an investigational gene editing therapy for adults with chronic hepatitis B.

Precision BioSciences (DTIL) announced that the FDA has granted fast track designation for PBGENE-HBV, the company’s lead wholly owned in vivo ...

In April 2025, Vir Biotechnology Inc. announced a phase 1b/2 platform study framework to evaluate the safety and efficacy of ...

The company is dedicated to educating patients, providers, and others on new findings in chronic hepatitis B virus (HBV) infection. Chronic HBV infection is the most common viral infection in ...

Chronic HBV was associated with increased risk for adverse COVID-19 outcomes, but the risk was lower among coinfected patients vaccinated against COVID-19.

Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface ...

Results Patients with hepatitis B (HBV) were more likely to develop HCC at a younger age than patients with hepatitis C (HCV) (HBV-26% under age 40, HCV-0% under age 40; p < 0.001), with greater ...